UNSPSC 51361806: Midaflur

This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 840CTL676L. European Medicines Agency schedules Midaflur in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08946MIG. Midaflur generally arises in the molecular formula C8H4F12N2. The term MIDAFLUR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 12 no. 2 1999, list 40.) Most nations schedule midaflur under HS 29332990 and SITC 51573.

As of Q4 2014, MIDAFLUR remains the US FDA Preferred Term for this commodity. Midaflur bears US NLM identifiers UMLS ID C0066528 and NCI Concept Code C90942. SMILES: FC(F)(F)C1(NC(C=C1N)(C(F)(F)F)C(F)(F)F)C(F)(F)F.

UNSPSC 51361806 Midaflur, a Commodity code, does not align with state and local procurement activity in the recent opportunities block. The three most recent solicitations under this code tag involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic pharmaceuticals with over-the-counter products—none of which are midaflur-specific or define a coherent purchasing category. The code shows little relevant recent activity, and the mismatch between the code's nominal scope and the work actually being solicited suggests either a data classification error or abandonment of this specific UNSPSC category in favor of broader pharmaceutical or public-health-goods codes.

The three posted opportunities span a county health department, a state HHS commission, and a multi-state cooperative purchasing alliance, with activity in Florida and Texas, but none of these solicitations target midaflur as a distinct product line. Seminole County, Florida issued an IFB for naloxone and safe drug deactivation systems with a response deadline of July 26, 2023 (now expired), the Texas Health and Human Services Commission posted an RFI on direct-to-manufacturer prescriptions with a response deadline of April 3, 2026, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic pharmaceuticals and OTC products due March 26, 2026. Without recent solicitations specifically targeting midaflur, the code does not present a clear procurement signal for firms evaluating entry or portfolio priority in state and local government markets.